Switching from Mounjaro to Wegovy pills: what actually changes
A different molecule, a different route and a daily routine that is far less forgiving. Your dose does not carry across, and neither does your tolerance.
In one paragraph: Mounjaro is tirzepatide, a weekly injection acting on two receptors. The Wegovy pill is oral semaglutide, a daily tablet acting on one. They are different medicines, so no dose converts across and a switch normally means restarting at the lowest oral strength and titrating up regardless of where you were. Expect gut side effects to return during that build up, because tolerance is medicine specific. On average, head to head trial evidence favours tirzepatide for weight loss, so a switch is usually made for cost, supply, tolerability or needle related reasons rather than for better results. The decision belongs to your prescriber, and the timing of the last injection and the first tablet is part of that conversation.
These are not two versions of the same drug
The most common misunderstanding is treating this as a change of format. It is a change of medicine.
Tirzepatide activates both the GLP-1 and GIP receptors. Semaglutide activates GLP-1 only. That difference is why milligram figures are meaningless across the two: 10mg of tirzepatide has no oral semaglutide equivalent, and asking to start at something matching your old dose is asking for a rough few weeks with no upside.
The second difference is absorption. An injection delivers a predictable amount regardless of your morning. An oral tablet does not, which is why the empty stomach rule exists and why it is not optional.
Mounjaro, as you have been taking it
- Tirzepatide, a dual GIP and GLP-1 receptor agonist
- One injection per week, any time of day, with or without food
- A missed dose has a window of several days
- Storage and sharps disposal to manage
The Wegovy pill, as it will be
- Semaglutide, a GLP-1 receptor agonist, taken orally
- One tablet every day, first thing, on an empty stomach
- A sip of plain water only, then 30 minutes before anything else
- A missed dose is skipped, never doubled
What the evidence says about the difference
People switching deserve a straight answer on results rather than reassurance. The full side by side, including routine and live tablet prices, sits on Wegovy pill vs Mounjaro.
The only head to head trial between these molecules compared the injections. In SURMOUNT-5, published in the New England Journal of Medicine and led by Louis Aronne, adults with obesity and without type 2 diabetes lost an average of 20.2 per cent of body weight on tirzepatide against 13.7 per cent on injectable semaglutide at 72 weeks.
For the oral form, the OASIS 4 trial of once daily oral semaglutide 25mg, published in the New England Journal of Medicine in September 2025, reported average weight loss of 13.6 per cent at 64 weeks in the treatment policy analysis, and 16.6 per cent among participants who took the tablets as intended.
These are separate trials with different populations and durations, so the numbers should be read as a general direction rather than a precise gap. The direction is still clear: on average, people lose more on tirzepatide. That average cannot tell you how you will respond. It also says nothing about the medicine you can afford to stay on for two years, which usually matters more.
Reasons people actually switch
Cost
The most common reason by far. Prices for both change frequently and by provider, so the comparison worth making is your current total monthly cost against the Wegovy pill at the strength you would end up on, not at the starter strength.
Needles
Some people manage injections for months and then stop being able to. A daily tablet removes injections, sharps bins and fridge logistics entirely, which for a minority is the difference between treatment and no treatment.
Injection site problems
Persistent site reactions, bruising or lumps are a legitimate clinical reason to move to an oral option, and worth raising with a prescriber rather than tolerating.
Supply and continuity
Repeated gaps caused by stock issues do more damage than a modest difference in average efficacy. Being able to source your medicine reliably is part of how well it works.
Eligibility or prescriber policy
Not every service offers every medicine, and criteria differ. Sometimes a switch comes down to which medicine a provider will prescribe for you, not free choice.
How the changeover normally runs
The specifics belong to your prescriber, but the shape of it is fairly consistent across services.
You stop the weekly injections rather than tapering. Most services then begin the tablets around the point the next injection would have been due, which avoids both a long gap and any overlap of two GLP-1 medicines. Two of these medicines should never run together.
You start at the lowest oral strength and step up on the schedule your prescriber sets, in the same way you originally titrated your injection. Appetite suppression during the first few weeks will be weaker than you are used to, which is expected rather than a sign the switch has failed. Judge it once you reach a maintenance strength, not in week two.
Tirzepatide clears from the body gradually rather than instantly, so the first days after your last injection are usually comfortable. The dip most people notice arrives a couple of weeks in, once the old medicine has gone and the new one has not yet built up.
Tell your prescriber before switching if
- You take insulin or a sulfonylurea, since doses often need reviewing and hypo risk changes. See our low blood sugar guide.
- You take levothyroxine or any medicine with a narrow absorption window, because the 30 minute rule affects the whole morning routine.
- You have had pancreatitis, gallbladder problems or severe gastrointestinal disease.
- You are pregnant, planning pregnancy or breastfeeding.
- You had significant side effects on tirzepatide, since some will recur.
The routine change people underestimate
Weekly to daily is a bigger adjustment than it sounds, and it is the part most switchers report struggling with rather than the medicine itself.
The tablet goes first thing, on an empty stomach, with a small amount of plain water, and nothing else for 30 minutes. Not tea, not coffee, not your other morning tablets. Anchor it to something you already do at a fixed time, and see our guides on taking the Wegovy pill and what to do after a missed dose before your first week rather than after it.
Questions people actually ask
What dose of the Wegovy pill matches my Mounjaro dose?
There is no matching dose. The molecules are different and the strengths do not convert. Expect to start at the lowest oral strength and build up, however long you were on tirzepatide.
Will I regain weight during the changeover?
Some people see a small regain or a plateau while the new medicine builds up, particularly in weeks two to six. This is common and usually temporary. It is not a reason to abandon the switch before you reach a maintenance strength.
Can I take both for a week to bridge the gap?
No. Two GLP-1 medicines should not be taken together. If timing worries you, ask your prescriber to plan the changeover date rather than improvising an overlap.
Do I need a new consultation?
Yes. A change of medicine requires a prescribing decision, which means a consultation with the service supplying it. If you are also changing pharmacy, our guide to switching pharmacy covers what evidence to send.
Can I switch back if it does not suit me?
That is a prescriber decision and generally possible, but going back also means re-titrating. Give the tablets a fair run to a maintenance strength before deciding they do not work for you.
Is the pill cheaper than Mounjaro?
Sometimes, and it varies by provider and strength. Compare on your likely maintenance strength rather than the starter price, and compare the total checkout cost including consultation and delivery rather than the headline.
Sources
- SURMOUNT-5, Aronne and colleagues, published in the New England Journal of Medicine: average weight loss of 20.2 per cent with tirzepatide against 13.7 per cent with injectable semaglutide at 72 weeks in adults with obesity without type 2 diabetes.
- OASIS 4 trial of once daily oral semaglutide 25mg, published in the New England Journal of Medicine, September 2025: mean weight loss of 13.6 per cent at week 64 in the treatment policy analysis and 16.6 per cent with full adherence.
- NHS prescribing guidance for oral semaglutide: the tablet is swallowed whole on an empty stomach with a small amount of water and no food, other drink or other oral medicines for 30 minutes afterwards.
- The Patient Information Leaflet supplied with your medicine, and the prescriber or pharmacist responsible for your care, which take precedence over any general guidance on this page.
Compare before you commit to the switch
Check the Wegovy pill at the strength you would settle on, not the starter dose, across every verified UK pharmacy.
This page is general information about prescription only medicines and is not medical advice, a diagnosis or a recommendation to start, stop or change treatment. Ogovy does not sell, prescribe or dispense medicines. Any change of medicine is a decision for you and a qualified prescriber. Ogovy is operated by Medstack Ltd and is independent of every pharmacy it lists.
